Get the Stockscreener App
22.80
2.83%
-0.5601
Instil Bio Inc stock is traded at $22.80, with a volume of 34,385.
It is down -2.83% in the last 24 hours and down -34.96% over the past month.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
See More
Previous Close:
$23.36
Open:
$24
24h Volume:
34,385
Relative Volume:
0.12
Market Cap:
$160.14M
Revenue:
-
Net Income/Loss:
$-156.09M
P/E Ratio:
-16.06
EPS:
-1.42
Net Cash Flow:
$-102.69M
1W Performance:
-22.89%
1M Performance:
-34.96%
6M Performance:
+103.16%
1Y Performance:
+6,102%
1-Day Range:
$22.53
$24.90
1-Week Range:
$22.53
$29.35
52-Week Range:
$0.3035
$92.00
Instil Bio Inc Stock (TIL) Company Profile
Name
Instil Bio Inc
Sector
Industry
Phone
(972) 499-3350
Address
3963 MAPLE AVENUE, DALLAS
Compare TIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| TIL | 22.58 | 160.14M | 0 | -156.09M | -102.69M | -1.42 |
| VRTX | 446.78 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 737.75 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 586.52 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.92 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.55 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Instil Bio Inc Stock (TIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-01-22 | Downgrade | Truist | Buy → Hold |
| Aug-13-21 | Initiated | Robert W. Baird | Outperform |
| Apr-13-21 | Initiated | Cowen | Outperform |
| Apr-13-21 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-21 | Initiated | Truist | Buy |
View All
Instil Bio Inc Stock (TIL) Latest News
(TIL) Trading Report - Stock Traders Daily
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Instil Bio Secures Global Rights to PD-L1xVEGF Drug, Reports $122.9M Cash Position | TIL Stock News - StockTitan
2 Stocks Up Over 700% in 2024 That Could Soar Even Further - AOL
(TIL) Technical Data - Stock Traders Daily
JMP Securities initiates Instil Bio shares at Market Perform on public offering - Investing.com Australia
Instil Bio, Inc.'s (NASDAQ:TIL) stock price dropped 18% last week; private equity firms would not be happy - Simply Wall St
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising? - The Motley Fool
Analysis of Curative Ventures V LLC's Strategic Reduction in Instil Bio Inc - GuruFocus.com
(TIL) Long Term Investment Analysis - Stock Traders Daily
Baird maintains price target on Instil Bio stock, stays upbeat - Investing.com
5 Top NASDAQ Biotech Stocks of 2024 - Nasdaq
FDA Oncology Approvals Accelerate as Global Cancer Rates Set to Climb 77% - Baystreet.ca
Instil Bio Stock Skyrockets 641% in One Week: Here's Why - MSN
BOXER CAPITAL, LLC Acquires New Stake in Instil Bio Inc - GuruFocus.com
Perceptive Advisors LLC Acquires New Stake in Instil Bio Inc - GuruFocus.com
Baird sees Instil Bio stock upside on promising SYN-2510 clinical data - Investing.com
Fantastic Fest 2024: Clowns Rule at Texas’ No-Joke Genre Event Set to Debut ‘Terrifier 3,’ ‘V/H/S Beyond,’ and More - IndieWire
B. Riley Analysts Decrease Earnings Estimates for Inspired Entertainment, Inc. (NASDAQ:INSE) - Defense World
The time has not yet come to remove your chips from the table: Instil Bio Inc (TIL) - SETE News
Financial Metrics Unveiled: Instil Bio Inc (TIL)’s Key Ratios in the Spotlight - The Dwinnex
Instil Bio (TIL) Stock Rises In Extended Session On Major Strategy Reveal - Stocks Telegraph
Inspired Entertainment, Inc. to Post Q3 2024 Earnings of $0.22 Per Share, B. Riley Forecasts (NASDAQ:INSE) - Defense World
Ice Nine Kills to Release Official Song for Slasher Film Terrifier 3 - MetalSucks
Baird retains price target, outperform rating on Instil Bio shares By Investing.com - Investing.com Australia
Ice Nine Kills are releasing a new single for Terrifier 3 - Kerrang!
Ice Nine Kills’ Upcoming Single “A Work of Art” to Feature on "Terrifier 3" Soundtrack - Ghost Cult Magazine
Here's Why Everyone's Talking About Summit Therapeutics - MSN
This is why everyone is talking about Summit TherapeuticsTHE BHARAT EXPRESS NEWS - The Bharat Express News
Instil Bio stock target raised by H.C. Wainwright on cancer drug outlook - Investing.com
instilbiocorppres2024091.htm - SEC.gov
ICE NINE KILLS announce new 'TERRIFIER'-themed single and video starring SHAVO ODADJIAN - Revolver Magazine
Official 'Terrifier 3' Music Video from Ice Nine Kills Slashing into Fantastic Fest & AMC Theatres! - Bloody Disgusting
Crude Oil Surges Over 1%; Instil Bio Shares Plunge - MSN
Baird retains price target, outperform rating on Instil Bio shares - Investing.com India
Instil Bio Inc (TIL) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Baird positive on Instil Bio’s SYN-2510 development strategy - TipRanks
Do investors need to be concerned about Instil Bio Inc (TIL)? - US Post News
Instil Bio Outlines Oncology Strategy and Collaborative Efforts - TipRanks
Instil Bio price target raised to $120 from $40 at H.C. Wainwright - TipRanks
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer - Yahoo Finance
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? - sharewise
Baird ups Instil Bio shares target as PD-1/L1xVEGF space gains momentum - Investing.com India
Summit lifts Instil, BioNTech on Merck beating data (NASDAQ:SMMT) - Seeking Alpha
Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements (TIL) - Seeking Alpha
Instil Bio surges after Baird target calls for shares tripling - TipRanks
(TIL) On The My Stocks Page - Stock Traders Daily
Instil Bio’s Stock Price Target (NASDAQ: TIL) Get’s A Big Uplift From Baird - AskTraders
H.C. Wainwright raises Instil Bio shares target with Buy rating By Investing.com - Investing.com Australia
Instil Bio price target raised to $180 from $32 at Baird - TipRanks
Instil Bio Inc Stock (TIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):